Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629758 · ClinicalTrials.gov registry record · Phase 1
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
A Phase 1 study of Neoplasms by Site, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 5
- Study locations
NCT01629758: Completed Phase 1 study of Neoplasms by Site, sponsored by Bristol-Myers Squibb.
NCT01629758 is a Phase 1 study of Neoplasms by Site that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants, below the 509-participant average among 11 other Neoplasms by Site trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01629758, a Phase 1 study of Neoplasms by Site, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Denenicokin
Study Locations (5)
Arizona
- Oncology Research Associates, Pllc D/B/A - Scottsdale
Connecticut
- Yale University School Of Medicine - New Haven
Florida
- Moffitt Cancer Center - Tampa
Maryland
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT01629758 record still lists
NCT01629758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 509-participant average among 11 other Neoplasms by Site trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Neoplasms by Site appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT01629758 lists 5 locations in 5 states (Arizona, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT01629758 about?
NCT01629758 is a clinical study titled "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors". The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
What is the current status of trial NCT01629758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-06. Estimated completion is 2014-12.
What conditions does trial NCT01629758 study?
This clinical trial studies the following conditions: Neoplasms by Site.
What interventions are being tested in trial NCT01629758?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Denenicokin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01629758?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01629758 being conducted?
This trial has 5 study locations across Arizona, Connecticut, Florida, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms by Site
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01629758's enrollment target sits among peer trials
33 10th of 11 higher than 2 of 11 other Neoplasms by Site trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms by Site trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
RECRUITING · Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia